622 related articles for article (PubMed ID: 26921160)
1. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
[TBL] [Abstract][Full Text] [Related]
2. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea.
Roumie CL; Min JY; Greevy RA; Grijalva CG; Hung AM; Liu X; Elasy T; Griffin MR
CMAJ; 2016 Apr; 188(6):E104-E112. PubMed ID: 26811361
[TBL] [Abstract][Full Text] [Related]
3. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
[TBL] [Abstract][Full Text] [Related]
5. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline.
Hung AM; Roumie CL; Greevy RA; Grijalva CG; Liu X; Murff HJ; Ikizler TA; Griffin MR
Clin J Am Soc Nephrol; 2016 Dec; 11(12):2177-2185. PubMed ID: 27827311
[TBL] [Abstract][Full Text] [Related]
7. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
Jil M; Rajnikant M; Richard D; Iskandar I
Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
[TBL] [Abstract][Full Text] [Related]
8. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.
Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Murff HJ; Elasy TA; Griffin MR
JAMA; 2014 Jun; 311(22):2288-96. PubMed ID: 24915260
[TBL] [Abstract][Full Text] [Related]
9. Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study.
Roumie CL; Min JY; D'Agostino McGowan L; Presley C; Grijalva CG; Hackstadt AJ; Hung AM; Greevy RA; Elasy T; Griffin MR
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28424149
[TBL] [Abstract][Full Text] [Related]
10. Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes.
Alexopoulos AS; Kahkoska AR; Pate V; Bradley MC; Niznik J; Thorpe C; Stürmer T; Buse J
JAMA Netw Open; 2021 Nov; 4(11):e2132215. PubMed ID: 34726745
[TBL] [Abstract][Full Text] [Related]
11. Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.
Htoo PT; Paik JM; Alt E; Kim DH; Wexler DJ; Kim SC; Patorno E
J Gerontol A Biol Sci Med Sci; 2023 Dec; 78(12):2426-2434. PubMed ID: 36866496
[TBL] [Abstract][Full Text] [Related]
12. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
[TBL] [Abstract][Full Text] [Related]
13. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
14. Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease.
Marcum ZA; Forsberg CW; Moore KP; de Boer IH; Smith NL; Boyko EJ; Floyd JS
J Gen Intern Med; 2018 Feb; 33(2):155-165. PubMed ID: 29181788
[TBL] [Abstract][Full Text] [Related]
15. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
[TBL] [Abstract][Full Text] [Related]
16. Hypoglycemia in hospitalized patients treated with sulfonylureas.
Deusenberry CM; Coley KC; Korytkowski MT; Donihi AC
Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146
[TBL] [Abstract][Full Text] [Related]
17. Sulfonylureas as second line therapy for type 2 diabetes among veterans: Results from a National Longitudinal Cohort Study.
Weeda ER; Ward R; Gebregziabher M; Chandler O; Strychalski ML; Axon RN; Taber DJ
Prim Care Diabetes; 2023 Aug; 17(4):386-391. PubMed ID: 37121788
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
19. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients.
Williams SA; Shi L; Brenneman SK; Johnson JC; Wegner JC; Fonseca V
J Diabetes Complications; 2012; 26(5):399-406. PubMed ID: 22699113
[TBL] [Abstract][Full Text] [Related]
20. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
